AVEA’s 2-year journey has been an exhilarating ride, marked by remarkable achievements and growth. From achieving EBIT positivity and expanding their team, becoming the fastest growing longevity brand in Europe to exploring new markets, their milestones speak volumes about their…

We're thrilled to welcome Thanh Schrader-Nguyen to the Maximon family and Frieda Health team! 🚀 With a wealth of experience in women's health and venture building, Thanh brings over a decade of expertise in digital product design, management, and a solid background in medtech, including…

Looking forward to our VC panel at the „Rejuvenation Startup Summit“ in Berlin

#longevity #rejuvenation #aging

Join us at the Swiss Biotech Day on April 22-23, 2024, at Congress Center Basel, Switzerland. We're thrilled to announce that Elisabeth Roider, MD, PhD, MBA, Partner & CSO/CMO at Maximon, will be part of a dynamic plenary panel discussing longevity. Join Elisabeth alongside esteemed experts Patrick…

🌟 Exciting news! 🌟 Maximon's Founding Partner, Marc P. Bernegger 👾 MP₿, will be sharing insights at the upcoming Zero One Hundred Conferences (PE & VC Platform) Europe 2024 in Amsterdam. Join him for a panel on 'Strategic Investment in Longevity' on Wednesday, April 17th, as he dives deep into the future of…

Check out the guest article on finews.ch from our Founding Partner Dr. Tobias Reichmuth about 'Longevity as the biggest investment opportunity of the century'

finews.com/news/english-n…

Due to the high demand we extended the subscription deadline of our longevity certificate and professional investors will find more details here

maximon.com/post/marcuard-…

Join us at START Summit in St. Gallen on March 21st for a panel on longevity: 'Building longer lives.' 💡 Marc P. Bernegger 👾 MP₿ and Dr. Tobias Reichmuth, Founding Partners of Maximon, will be sharing insights alongside Aksana Labokha, CEO of Rejuveron Life Sciences.

Longevity Investors announces Longevity Investors Conference 2024
Longevity Investors 2024 set to return to Gstaad, Switzerland in September, this year in a longer format.
Marc P. Bernegger 👾 MP₿ @tobiasreichmuth #event #investment #economy #longevity
longevity.technology/news/longevity…

Marcuard Heritage, GenTwo and Maximon offers access to longevity assets for investors Eva Novak Maximon GenTwo Dr. Tobias Reichmuth
Accessible only for some: minimum of US$10,000 to invest in longevity breakthroughs #Investment #longevity
liveforever.club/article/marcua…

Launch of a new longevity-related investment opportunity for investors in Switzerland and the EU.
If you are considering investing some 💰️ in longevity companies, read our piece to learn more 👇️
lifespan.io/news/lowering-…
By Steve Hill
#aging #longevity #investing

Maximon and AYUN Healthspan featured in FOCUS online. Elisabeth Roider, MD, PhD, MBA, Partner & CSO/CMO at Maximon, and Leonie Bode, Co-Founder & Medical Director of AYUN, shared what is important for healthy aging! 💪🍃

Check out the insightful interview now: bit.ly/491BSnn

Join us at turnaroundaging where Maximon's Partner & CSO/CMO, Elisabeth Roider, MD, PhD, MBA, will delve into the future of longevity therapies on stage. That’s not all - our Advisor, Nina Ruge, will kickstart the event with a captivating keynote on Healthy Longevity.

We're proud to be part of…

We are delighted to announce that Nikolay Milev, Scientific Analyst at Maximon, will be presenting at Trendtage Gesundheit Luzern on Thursday, March 7th! 🎤Nikolay will explore the topic of 'Decomplexifying Multimodal Diagnostics: A Pathway Towards Personalized Health.' 🌟

Maximon lowers the bar for European longevity investors
More professional investors in Europe can now participate in the Longevity Co-Investment Fund, with minimum investment reduced to CHF 10,000.
Maximon #longevity #investment #investing
longevity.technology/news/maximon-l…

Marcuard Heritage, GenTwo and Maximon are excited to announce the launch of a new investment opportunity for professional investors to get exposure to Maximon's portfolio of longevity ventures

maximon.com/post/marcuard-…

🔬🌟 Proud to be part of groundbreaking research! 🌟🔬

Our Chief Scientific and Medical Officer, Elisabeth Roider, MD, PhD, MBA, led a new study published in JAMA . The team developed a mathematical model revealing the staggering economic burden of delayed cancer diagnoses, using the…